You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

401 Results
Document
Jan 2025
Document
Jan 2025
Document
Jan 2025
The Radiation Treatment Program ensures timely access to safe, evidence-based, high-quality radiation treatment. To improve patient experience and...
Drug
Other Name(s): Sarclisa®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Mar 2024
Drug
Other Name(s): Jakavi®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Mar 2025
Regimen
Cancer Type:
Hematologic, 
Myeloproliferative Neoplasms (MPNs)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    ruxolitinib - For patients with intermediate to high risk symptomatic myelofibrosis, or patients with symptomatic splenomegaly, according to specific criteria
Exceptional Access Program
    ruxolitinib - For the treatment of patients with polycythemia vera according to criteria.
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
ruxolitinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2025
Recognizing the challenge and opportunity of take-home cancer medications, Cancer Care Ontario hosted a policy planning and consultation session in...

Pages